GlaxoSmithKline Historical Income Statement

GSK Stock

USD 36.17 0.38 1.04%

Historical analysis of GlaxoSmithKline PLC income statement accounts such as Total Revenue of 19.9 B or Gross Profit of 14.6 B can show how well GlaxoSmithKline PLC ADR performed in making a profits. Evaluating GlaxoSmithKline PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of GlaxoSmithKline PLC's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Income Statement Analysis

GlaxoSmithKline PLC ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to GlaxoSmithKline PLC shareholders. The income statement also shows GlaxoSmithKline investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

GlaxoSmithKline PLC Income Statement Chart

At this time, GlaxoSmithKline PLC's Discontinued Operations is quite stable compared to the past year. Extraordinary Items is expected to rise to about 12.7 B this year, although the value of Gross Profit will most likely fall to about 14.6 B.

Operating Income Total Other Income Expense Net Net Income Applicable To Common Shares Selling And Marketing Expenses Non Recurring Reconciled Depreciation

Operating Income

Operating Income is the amount of profit realized from GlaxoSmithKline PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of GlaxoSmithKline PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from GlaxoSmithKline PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2022	2023	2024	2025 (projected)
Interest Expense	879M	775M	891.3M	502.2M
Depreciation And Amortization	2.1B	2.3B	2.6B	2.8B

Interest Expense Depreciation And Amortization

GlaxoSmithKline PLC income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Cost Of Revenue	Minority Interest	Selling And Marketing Expenses	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.25	0.21	0.28	0.12	0.49	0.13	0.65	0.44	0.14	0.48	0.32	0.58	0.0	0.27	0.13	0.01	-0.35	0.17	-0.09	-0.68	-0.1	-0.15
Interest Expense	0.25		0.94	0.93	0.91	0.69	0.76	0.56	0.8	0.89	0.6	-0.01	0.58	0.25	0.81	0.87	0.09	-0.89	0.01	-0.31	-0.13	-0.39	0.18
Total Revenue	0.21	0.94		0.99	0.98	0.58	0.69	0.64	0.72	0.96	0.49	-0.15	0.46	0.11	0.9	0.94	-0.03	-0.85	-0.12	-0.56	-0.17	-0.45	0.18
Gross Profit	0.28	0.93	0.99		0.94	0.58	0.66	0.7	0.71	0.95	0.49	-0.19	0.46	0.13	0.88	0.89	-0.11	-0.85	-0.17	-0.54	-0.24	-0.4	0.08
Other Operating Expenses	0.12	0.91	0.98	0.94		0.5	0.66	0.58	0.65	0.98	0.41	-0.14	0.38	0.08	0.89	0.96	0.06	-0.84	-0.05	-0.58	-0.07	-0.4	0.2
Operating Income	0.49	0.69	0.58	0.58	0.5		0.88	0.46	0.97	0.45	0.99	0.61	0.97	0.58	0.57	0.53	0.48	-0.6	0.52	0.05	-0.21	-0.24	0.04
Ebit	0.13	0.76	0.69	0.66	0.66	0.88		0.42	0.94	0.6	0.86	0.42	0.78	0.61	0.7	0.69	0.5	-0.68	0.44	-0.12	-0.05	-0.3	0.07
Research Development	0.65	0.56	0.64	0.7	0.58	0.46	0.42		0.54	0.62	0.39	-0.12	0.4	0.07	0.72	0.6	-0.17	-0.69	-0.11	-0.63	-0.68	-0.29	-0.22
Ebitda	0.44	0.8	0.72	0.71	0.65	0.97	0.94	0.54		0.61	0.94	0.5	0.91	0.52	0.69	0.67	0.45	-0.71	0.44	-0.1	-0.24	-0.31	0.04
Total Operating Expenses	0.14	0.89	0.96	0.95	0.98	0.45	0.6	0.62	0.61		0.36	-0.21	0.33	0.09	0.87	0.91	0.01	-0.85	-0.08	-0.59	-0.11	-0.28	0.05
Income Before Tax	0.48	0.6	0.49	0.49	0.41	0.99	0.86	0.39	0.94	0.36		0.68	0.97	0.63	0.49	0.44	0.55	-0.54	0.6	0.13	-0.18	-0.17	0.01
Total Other Income Expense Net	0.32	-0.01	-0.15	-0.19	-0.14	0.61	0.42	-0.12	0.5	-0.21	0.68		0.72	0.39	-0.03	-0.07	0.84	0.03	0.91	0.41	-0.01	0.02	0.03
Net Income	0.58	0.58	0.46	0.46	0.38	0.97	0.78	0.4	0.91	0.33	0.97	0.72		0.46	0.45	0.42	0.53	-0.49	0.6	0.13	-0.26	-0.24	0.04
Income Tax Expense	0.0	0.25	0.11	0.13	0.08	0.58	0.61	0.07	0.52	0.09	0.63	0.39	0.46		0.12	0.05	0.47	-0.33	0.49	0.34	0.17	0.34	-0.2
Selling General Administrative	0.27	0.81	0.9	0.88	0.89	0.57	0.7	0.72	0.69	0.87	0.49	-0.03	0.45	0.12		0.94	0.1	-0.82	0.0	-0.61	-0.21	-0.49	0.18
Cost Of Revenue	0.13	0.87	0.94	0.89	0.96	0.53	0.69	0.6	0.67	0.91	0.44	-0.07	0.42	0.05	0.94		0.11	-0.82	-0.01	-0.63	-0.1	-0.56	0.35
Minority Interest	0.01	0.09	-0.03	-0.11	0.06	0.48	0.5	-0.17	0.45	0.01	0.55	0.84	0.53	0.47	0.1	0.11		-0.09	0.96	0.25	0.18	0.06	0.07
Selling And Marketing Expenses	-0.35	-0.89	-0.85	-0.85	-0.84	-0.6	-0.68	-0.69	-0.71	-0.85	-0.54	0.03	-0.49	-0.33	-0.82	-0.82	-0.09		-0.06	0.33	0.16	0.19	-0.03
Net Income From Continuing Ops	0.17	0.01	-0.12	-0.17	-0.05	0.52	0.44	-0.11	0.44	-0.08	0.6	0.91	0.6	0.49	0.0	-0.01	0.96	-0.06		0.32	0.1	0.17	-0.05
Tax Provision	-0.09	-0.31	-0.56	-0.54	-0.58	0.05	-0.12	-0.63	-0.1	-0.59	0.13	0.41	0.13	0.34	-0.61	-0.63	0.25	0.33	0.32		0.43	0.53	-0.14
Interest Income	-0.68	-0.13	-0.17	-0.24	-0.07	-0.21	-0.05	-0.68	-0.24	-0.11	-0.18	-0.01	-0.26	0.17	-0.21	-0.1	0.18	0.16	0.1	0.43		0.31	0.33
Net Interest Income	-0.1	-0.39	-0.45	-0.4	-0.4	-0.24	-0.3	-0.29	-0.31	-0.28	-0.17	0.02	-0.24	0.34	-0.49	-0.56	0.06	0.19	0.17	0.53	0.31		-0.64
Reconciled Depreciation	-0.15	0.18	0.18	0.08	0.2	0.04	0.07	-0.22	0.04	0.05	0.01	0.03	0.04	-0.2	0.18	0.35	0.07	-0.03	-0.05	-0.14	0.33	-0.64

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	2.4B	2.1B	2.1B	2.3B	2.6B	2.8B
Interest Expense	892M	784M	879M	775M	891.3M	502.2M
Total Revenue	34.1B	34.1B	29.3B	30.3B	34.9B	19.9B
Gross Profit	22.4B	22.5B	19.8B	21.8B	25.0B	14.6B
Other Operating Expenses	26.3B	27.9B	22.9B	23.6B	27.1B	15.3B
Operating Income	7.8B	6.2B	6.4B	6.7B	7.8B	5.0B
Ebit	7.8B	5.6B	6.5B	6.8B	7.9B	5.5B
Research Development	5.1B	5.3B	5.5B	6.2B	7.2B	7.5B
Ebitda	10.2B	7.8B	8.6B	9.1B	10.5B	6.4B
Total Operating Expenses	14.6B	16.3B	13.3B	15.0B	17.3B	10.0B
Income Before Tax	7.0B	5.4B	5.6B	6.1B	7.0B	4.8B
Total Other Income Expense Net	956M	(758M)	(805M)	(681M)	(612.9M)	(582.3M)
Net Income	5.7B	4.4B	4.9B	4.9B	5.7B	3.4B
Income Tax Expense	580M	346M	707M	756M	869.4M	1.2B
Selling General Administrative	11.5B	11.0B	8.4B	9.4B	10.8B	9.8B
Cost Of Revenue	11.7B	11.6B	9.6B	8.6B	9.8B	7.7B
Net Income Applicable To Common Shares	4.6B	5.7B	4.4B	15.0B	13.5B	14.1B
Minority Interest	6.2B	(711M)	(665M)	(380M)	(437M)	(415.2M)
Net Income From Continuing Ops	6.4B	5.1B	4.9B	6.5B	5.9B	9.4B
Tax Provision	580M	346M	707M	756M	680.4M	669.3M
Interest Income	44M	723M	76M	48M	43.2M	41.0M
Net Interest Income	(848M)	(756M)	(803M)	(735M)	(661.5M)	(694.6M)
Reconciled Depreciation	2.4B	2.5B	2.3B	1.5B	1.4B	1.7B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.167

Dividend Share

0.61

Earnings Share

1.55

Revenue Per Share

15.392

Quarterly Revenue Growth

0.008

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Historical Income Statement

About GlaxoSmithKline Income Statement Analysis

GlaxoSmithKline PLC Income Statement Chart

Operating Income

Net Income Applicable To Common Shares

GlaxoSmithKline PLC income statement Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.99	Total Revenue
Income Before Tax	+ 0.99	Operating Income
Other Operating Expenses	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Other Operating Expenses
Ebitda	+ 0.97	Operating Income
Net Income	+ 0.97	Operating Income

Selling And Marketing Expenses	- 0.89	Interest Expense
Selling And Marketing Expenses	- 0.85	Total Operating Expenses
Selling And Marketing Expenses	- 0.85	Gross Profit
Selling And Marketing Expenses	- 0.85	Total Revenue
Selling And Marketing Expenses	- 0.84	Other Operating Expenses
Selling And Marketing Expenses	- 0.82	Cost Of Revenue